A Systematic Review and Network Meta-Analysis of Chinese Trials on Antihypertensive Medications for Managing Hyperuricemia in Hypertensive Patients - Summary - MDSpire
Advertisement
A Systematic Review and Network Meta-Analysis of Chinese Trials on Antihypertensive Medications for Managing Hyperuricemia in Hypertensive Patients
To synthesize global evidence on the urate-lowering efficacy of antihypertensive agents in hypertensive patients with hyperuricemia, addressing a critical gap in the literature.
Key Findings:
The prevalence of hyperuricemia among hypertensive patients in China is as high as 38.7%, indicating a significant public health concern.
Previous studies suggest inconsistent effects of antihypertensive agents on hyperuricemia, highlighting the need for further investigation.
Losartan was found to be more effective than other antihypertensive agents in reducing serum uric acid levels, suggesting its potential as a preferred treatment option.
Interpretation:
The findings highlight the need for effective antihypertensive treatments that also manage hyperuricemia, particularly in the Chinese population, where the prevalence is notably high, underscoring the importance of tailored treatment strategies.
Limitations:
The review is limited to Chinese RCTs, reflecting a gap in global evidence and potential biases in the included studies.
Variations in diagnostic thresholds for hyperuricemia across trials may affect generalizability.
Conclusion:
This systematic review provides evidence supporting the use of certain antihypertensive agents, particularly losartan, in managing hyperuricemia among hypertensive patients, while emphasizing the need for further research in diverse populations to enhance the applicability of findings.
